Oncozenge

Oncozenge EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Oncozenge (ONCOZ.ST) as of Oct 31, 2026 is -2.96. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -7.94 — a change of -62.75% (higher).

EV/FCF

-2.96

YoY

-62.75%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Oncozenge is 2025 -2.96 . EV/FCF (Enterprise Value to Free Cash Flow) of Oncozenge was 2024 -7.94 . It decreases by -62.75% higher compared to the previous year.

The Oncozenge EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2020
-63,481.08 SEK
Jan 1, 2021
-2.20 SEK
Jan 1, 2022
-2.01 SEK
Jan 1, 2023
-3.56 SEK
Jan 1, 2024
-7.94 SEK
Jan 1, 2025
-2.96 SEK
The Oncozenge EV/FCF history
YEAREV/FCFYoY
-2.96-62.75%
-7.94+122.99%
-3.56+77.37%
-2.01-8.68%
-2.20-100.00%
-63,481.08—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Oncozenge Stock analysis

What does Oncozenge do? OncoZenge AB develops BupiZenge, a bupivacaine lozenge formulation targeting oral pain from cancer treatments like radiotherapy and chemotherapy. The company focuses on clinical studies for regulatory approval, aiming to address oral mucositis, a severe complication requiring pain relief. BupiZenge is positioned as a solution for patients needing immediate relief during cancer therapy, with strategic efforts centered on its development and registration. OncoZenge AB targets healthcare providers and oncology centers that treat cancer patients experiencing oral mucositis. The firm's product addresses a specific clinical need, aligning with treatment protocols for cancer care. By developing a dedicated lozenge formulation, OncoZenge AB seeks to secure market access through regulatory pathways, focusing on the unmet demand in cancer pain management. Oncozenge is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Oncozenge stock

EV/FCF (Enterprise Value to Free Cash Flow) of Oncozenge is -2.96 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Oncozenge changed from -7.94 to -2.96, representing a -62.75% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Oncozenge since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Oncozenge with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Oncozenge

All Key Metrics — Oncozenge